

## METHODOLOGICAL NOTE

### 1. Introduction

Ferring regularly works with HCP/HCOs. This Methodological note provides a summary of the methodologies used by Ferring Pharmaceuticals Limited in line with the ABPI Code of Practice 2021 to identify and report on Transfers of Value made directly or indirectly by Ferring, to or for the benefit of HCP/HCOs.

### 2. Definitions

**HCP:** An individual who is qualified to prescribe, administer, purchase, supply or recommend a Medicinal Product whose primary practice, principal professional address or place of incorporation is in UK

**HCO:** Any legal person (i) that is a healthcare, medical or scientific association or organization (irrespective of the legal or organizational form) such as a hospital, clinic, foundation, university or other teaching institution or learned society, whose business address, place of incorporation or primary place of operation is in UK or (ii) through which one or more HCPs provide services.

**TOV:** Transfer of Value - Direct and indirect TOV, whether in cash, in kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development and sale of prescription only medicine exclusively for human use. Direct TOVs are those made directly by Ferring for the benefit of a Recipient. Indirect TOVs are those made on behalf of Ferring for the benefit of a Recipient, or those made through a Third Party and where Ferring knows or can identify the Recipient that will benefit from the Transfer of Value. Aggregate ToVs are those which cannot be disclosed on an individual basis for legal reasons; the amounts attributable to such ToVs will be disclosed on an aggregate basis. The aggregate disclosure identifies (i) the number of Recipients covered by such disclosure, and (ii) the total amount attributable to ToV to such Recipients.

**Donations, Grants:** Providing funds, benefits in-kind, or services freely given for the purpose of supporting healthcare, scientific research or education, with no consequent obligation on the recipient organisation, institution and the like to provide goods or services to Ferring to the benefit of Ferring in return. Donations and grants to HCPs are prohibited.

**Sponsorship:** a contribution, financial or otherwise, in whole or in part provided by or on behalf of Ferring, towards an activity (including an event/meeting or material) performed, organised, created etc by a healthcare organisation, patient organisation or other independent organisation.

**Support:** the provision of a financial contribution, in whole or in part, whether paid directly or indirectly to individual health professionals or other relevant decision makers to attend events/meetings, and includes payment for registration fees, travel and accommodation.

### 3. Completion of the ABPI Disclosure template

At the start of 2024 TOV disclosure data in respect of 2023 is inputted into the ABPI disclosure template from Financial Agreements and other payment agreements (research service agreements, consultancy agreements, market research studies where identity of HCP/HCO is known to Ferring)

made with the HCP/HCO and checked before uploading to the ABPI portal. Cross border transfer of values from Ferring affiliates for UK HCPs and HCOs are also included in the submission. If one HCP/HCO has several countries of practices / registration the country in which context the assignment took place discloses the transfers of value.

In case of partial attendance or cancellation, or services not delivered, but value was transferred anyway e.g. according to contract clause, the transferred value is disclosed. If no value was transferred, the information on the ToV is not part of disclosure.

How has consent been obtained

Consent to provide disclosure information of transfer of values is included as a part of the financial agreement/other payment agreement completed by the HCP/HCO with a clear privacy disclaimer. Ferring relies on legitimate interests as its lawful basis for publicly disclosing ToVs to HCPs, unless an HCP exercises their right to object to disclosure, and where such objection overrides Ferring's legitimate interests in disclosure.

#### 5. Tax considerations

It is the responsibility of the HCP/HCO to inform tax authorities of payments received as transfer of values from Ferring. Ferring is not responsible for providing information to tax authorities regarding payments made to HCPs and HCOs.

#### 4. VAT (included or not)

VAT is not included in the payments.

#### 5. Currency aspects

- Conversion rates:  
All 2023 payments were made either in UK Pound Sterling or Euros, Euro entries were converted to UK Pound Sterling by Ferring on the 19th March 2024 using the conversion rate of 0.85.

#### 6. Multi-year contracts

Only contracts with ToV where the payment was actually made in 2023 have been included in the 2023 disclosure. For contracts where the invoices are paid out in 2024, the disclosure will be made in 2024.

#### 7. Over-the-counter transfers of value? Are they/some included?

According to 2021 Code of Practice, these are not required to be disclosed (clause 1.25). Ferring didn't have any over-the-counter transfers of value.

8. Medical device transfers of value

No transfer of values were made for medical devices in 2023.